Halozyme to Participate in Upcoming Investor Conferences
MWN-AI** Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has announced its participation in several upcoming investor conferences featuring presentations by Dr. Helen Torley, President and CEO, along with investor meetings. These events offer an excellent opportunity for investors to gain insights into the company’s innovative strategies and future initiatives.
The conferences include the TD Cowen 46th Annual Healthcare Conference on March 3, 2026, where Dr. Torley will participate in a fireside chat at 8:10 AM PT in Boston, MA. Following that, she will appear at the Leerink Partners Global Healthcare Conference on March 10, 2026, at 10:00 AM PT. The Citizens Life Sciences Conference will feature her on March 11, 2026, at 8:20 AM PT in Miami, FL. Investors unable to attend in person can access live audio webcasts of the presentations on Halozyme’s Investor Relations website, with replays available for 90 days after the events.
Halozyme focuses on advancing biopharmaceutical solutions that enhance patient experiences and outcomes, particularly through its ENHANZE® drug delivery technology. This proprietary enzyme rHuPH20 allows for subcutaneous delivery of various medications, significantly reducing treatment burden while improving patient convenience. With over a million patients positively impacted and partnerships with key biopharmaceutical companies like Roche, Pfizer, and AbbVie, Halozyme is at the forefront of innovative drug delivery systems.
Additionally, Halozyme is expanding its portfolio with products utilizing Hypercon™ technology, which aims to enhance drug concentration and reduce administration volume for improved patient comfort. The company's commitment to developing advanced drug-device combinations, such as Hylenex® and XYOSTED®, aligns with its mission to improve treatment adherence and convenience for patients. For further information, visit their website or follow Halozyme on LinkedIn.
MWN-AI** Analysis
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is poised for significant investor engagement in March 2026, with participation in three notable investor conferences. CEO Dr. Helen Torley will present at the TD Cowen 46th Annual Healthcare Conference, the Leerink Partners Global Healthcare Conference, and the Citizens Life Sciences Conference, offering a platform for investors to gain insights on the company’s strategic direction and value proposition.
As a biopharmaceutical innovator, Halozyme has made a mark with its ENHANZE® drug delivery technology, which enables subcutaneous delivery of therapies, facilitating broader patient access and potentially improving treatment adherence. Given that ENHANZE® has positively impacted over one million patients through multiple commercialized products, investors should closely monitor any updates or strategic insights shared during these conferences.
Additionally, Halozyme's recent advancements in drug delivery through its Hypercon™ and Surf Bio technologies reflect a commitment to innovation. These technologies promise to redefine the administration of biologics, thereby expanding market opportunities and positioning Halozyme competitively within the pharmaceutical landscape. The partnerships with leading companies like Janssen, Eli Lilly, and Takeda enhance Halozyme’s credibility and mitigate risk through diversified revenue streams.
Furthermore, potential announcements regarding ongoing development programs and new commercial partnerships during these conferences can influence investor sentiment and stock performance. Participants should pay attention to how Halozyme communicates its progress in these areas, as they are critical for driving future growth.
In conclusion, the upcoming investor conferences are crucial for cultivating investor relationships and market confidence. Stakeholders are advised to consider buying opportunities ahead of these events, while monitoring regulatory updates and sector trends that may impact Halozyme's valuations in the near term. Investors should remain agile as new information becomes available post-conferences, adjusting their positions according to the insights shared.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
SAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, is scheduled to present and host investor meetings at the following investor conferences:
Event: | TD Cowen 46th Annual Healthcare Conference | |||
Format: | Fireside Chat and 1x1 Meetings | |||
Presentation Date: | Tuesday, March 3, 2026 | |||
Presentation Time: | 8:10am PT / 11:10am ET | |||
Location:
| Boston, MA
| |||
Event: | Leerink Partners Global Healthcare Conference | |||
Format: | Fireside Chat and 1x1 Meetings | |||
Presentation Date: | Tuesday, March 10, 2026 | |||
Presentation Time: | 10:00am PT / 1:00pm ET | |||
Location:
Event: Format: Presentation Date: Presentation Time: Location: | Miami, FL
The Citizens Life Sciences Conference Fireside Chat and 1x1 Meetings Wednesday, March 11, 2026 8:20am PT / 11:20am ET Miami, FL |
Live audio webcasts of the presentations will be available in the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V. and Skye Bioscience.
Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and the Surf Bio hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at?home and healthcare?provider settings. The development of the Surf Bio polymer?based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly and argenx.
Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.
For more information, visit www.halozyme.com and connect with us on LinkedIn.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com
SOURCE Halozyme Therapeutics, Inc.
FAQ**
"Halozyme Therapeutics Inc. HALO, can you discuss the anticipated impact of your Hypercon™ and Surf Bio technologies on your drug delivery portfolio and their expected timeline for commercialization?"
"Halozyme Therapeutics Inc. HALO, could you provide insights into recent partnerships with major pharmaceutical companies and how these collaborations are expected to drive growth in 20and beyond?"
"Halozyme Therapeutics Inc. HALO, what measures are being taken to ensure the scalability and adaptability of your ENHANZE® technology as you expand into new therapeutic areas?"
"Halozyme Therapeutics Inc. HALO, can you elaborate on the regulatory pathway for your ongoing development programs and how you plan to navigate potential challenges in the biopharmaceutical landscape?"
**MWN-AI FAQ is based on asking OpenAI questions about Halozyme Therapeutics Inc. (NASDAQ: HALO).
NASDAQ: HALO
HALO Trading
-0.31% G/L:
$67.71 Last:
357,641 Volume:
$68.22 Open:
